Fertility Preservation in Female Cancer Patients

Northwell Health

Status

Terminated

Conditions

Fertility

Treatments

Procedure: oocyte vitrification

Study type

Interventional

Funder types

Other

Identifiers

NCT01268592

10-204A

Details and patient eligibility

About

The purpose of this study is to preserve the fertility potential in females diagnosed with cancer by vitrifying (rapidly freezing) their oocytes (eggs) before undergoing treatment for their cancer.

Enrollment

16 patients

Sex

Female

Ages

14 to 42 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients must be 14-42 year old females with a cancer diagnosis.
Clearance letter from treating oncologist.
Approval by program oncologist or her designee.
Informed consent has to be signed after consultation with the program physician. Minors require consent of a parent or a legal guardian and assent from the participant.
Life expectancy (predicted by their malignancy) of 5 or more years.
Cancer diagnosis should have an expected cure rate of 50% or more, based upon clinico-pathologic features.

Exclusion criteria

Patients whose oncologist and the program oncologist concur that immediate oncologic care should be rendered, not allowing sufficient time for a course of gonadotropin therapy and egg retrieval.
FSH level >20 MIU/ml, indicating abnormal ovarian function.
Patients with stage IV cancers (*age appropriate women with stage IV advanced Hodgkin's Lymphoma will be considered, as there is a significant long term survival rate with this advanced disease).
Patients with incurable cancer diagnoses.
Patients who are unable or unwilling to sign the informed consent.
Women cannot have an embryo transfer beyond age 50.